Darya-Varia Laboratoria Tbk PT
IDX:DVLA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 390
1 810
|
| Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Darya-Varia Laboratoria Tbk PT
Darya-Varia Laboratoria Tbk PT
Total Receivables
Darya-Varia Laboratoria Tbk PT
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
|
Total Receivables
Rp724B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
Total Receivables
Rp1.7T
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Kalbe Farma Tbk PT
IDX:KLBF
|
Total Receivables
Rp5.7T
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Soho Global Health Tbk PT
IDX:SOHO
|
Total Receivables
Rp1.7T
|
CAGR 3-Years
10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Pyridam Farma Tbk PT
IDX:PYFA
|
Total Receivables
Rp617.5B
|
CAGR 3-Years
85%
|
CAGR 5-Years
68%
|
CAGR 10-Years
33%
|
|
|
Kimia Farma Tbk PT
IDX:KAEF
|
Total Receivables
Rp2.3T
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
12%
|
|
Darya-Varia Laboratoria Tbk PT
Glance View
PT Darya-Varia Laboratoria Tbk engages in the manufacture and trade of pharmaceutical products and cosmetics. The company is headquartered in Jakarta, Dki Jakarta and currently employs 1,274 full-time employees. Its segments include prescription drugs, consumer health products, and export and toll manufacturing services. The firm provides products and services for consumer health, skin nutrition, respiratory, vitamins and daily relief. The Company’s products include Remscar (silicone gel), Carvilol, Ondavar (antiemetic), Etorix, Forti-D (vitamin D supplement), Decolgen, Neozep, Stop Cold, Decolsin, and Allerin. The Carvilol is used for heart health and treating hypertension. Ondavar is an antiemetic product used for nausea and vomiting during pregnancy. Etorix is a pain reliever. Forti-D is a supplement to fulfill the body’s need for vitamin D3. Darya-Varia provides a range of brands such as Enervon-C, Enervon Active, and Supertin that helps to boost body immune and maintain health. The firm also provides Imunped as supplement for kids with Zinc and vitamin C for children.
See Also
What is Darya-Varia Laboratoria Tbk PT's Total Receivables?
Total Receivables
724B
IDR
Based on the financial report for Sep 30, 2024, Darya-Varia Laboratoria Tbk PT's Total Receivables amounts to 724B IDR.
What is Darya-Varia Laboratoria Tbk PT's Total Receivables growth rate?
Total Receivables CAGR 10Y
5%
Over the last year, the Total Receivables growth was 35%. The average annual Total Receivables growth rates for Darya-Varia Laboratoria Tbk PT have been -3% over the past three years , 3% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet
